Why Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Are Better Than They Seem

Despite posting healthy earnings, Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276 ) stock has been quite weak. We have done some analysis, and found some encouraging factors that we believe the sha

Simply Wall St07:42

Haitong International: Free circuit with long slopes and heavy snow, domestic market space is expected to open up

The Zhitong Finance App learned that Haitong International released a research report saying that compared with innovative domestic drugs to replace relatively mature oncology drugs, self-exempt drugs also have the advantage of a large market size (suitable for the domestic pricing environment for new drugs). The differences are that patients are widely distributed (channel coverage is required), are more chronic diseases, and there is competition for traditional drugs (requiring fast efficacy and high accessibility). Combined with the current market financing environment, although the self-defense target layout is still crowded, companies with good cash flow will be more likely to obtain excess profits. It is recommended to pay attention to Hengrui Pharmaceutical (600276.SH), Kangzhe Pharmaceutical (00867), Sansheng Guojian (688)

Zhitong FinanceApr 25 21:09

Huayuan Securities released a research report on April 25 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) leading domestic pharmaceutical companies entering a new cycle of comprehensiv

Huayuan Securities released a research report on April 25 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) leading domestic pharmaceutical companies entering a new cycle of comprehensive innovation and transformation; 2) collection pressure has been basically adjusted; 3) the innovative R&D pipeline layout is comprehensive, or welcoming a new harvest period. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 25 17:37

Hengrui Pharmaceutical's 2023 performance rebounded steadily, and the sales expense ratio declined year-on-year

On the evening of April 17, Hengrui Pharmaceutical released its 2023 annual report. In 2023, Hengrui Pharmaceutical achieved operating income of 22.82 billion yuan, up 7.26% year on year, net profit attributable to shareholders of listed companies of 4.302 billion yuan, up 10.14% year on year, deducted non-net profit attributable to shareholders of listed companies of 4.141 billion yuan, up 21.46% year on year, net operating cash flow of 7.644 billion yuan, a sharp increase of 504.12% year on year. According to the report's analysis, as Hengrui Pharmaceutical's innovative achievements continue to be approved, the clinical value of innovative drugs is highlighted, driving revenue growth. 2023

China InvestorsApr 25 16:33

Express News | Hengrui Pharmaceutical: Obtained the Notice of Approval for Clinical Trials of Medon Insulin Injection Drugs

BreakingsApr 25 16:12

Hengrui Pharmaceutical (600276): The share of innovative drug revenue continues to increase, and the internationalization process is progressing steadily

Key investment events: The company released its 2023 annual report, achieved revenue of 22.82 billion yuan in 2023 (+7.26%, year-on-year growth rate in parentheses, same below); achieved net profit of 4.302 billion yuan (+10.1)

東吳證券Apr 24 16:01